Clinical PROTAC degraders of AR and ER with minor off-target toxicities harbor favorable pharmacokinetic profiles and are well-tolerated by heavily pretreated patients with advanced/refractory prostate or ER+/HER2- breast cancer, respectively. Here, AR is linked to breast carcinoma.